[NEWSMP] Publicly traded pharmaceutical companies, which had experienced a significant slowdown in growth due to the COVID-19 endemic and medical crisis, successfully rebounded in the third quarter.
Newsmp compiled third-quarter reports from listed pharmaceutical companies with fiscal year-ends in November and December and found that the combined sales of the 63 companies increased by 9.8% year-on-year.
Notably, even excluding Yuhan Corporation, which saw a significant increase in Q3 sales due to milestone payments for Leclaza, the combined sales growth rate of the remaining 62 companies was 8.4%, showing a significant improvement compared to the first half of the year when it was below 5%.
However, the growth rate varied significantly depending on company size. While large and medium-sized companies showed substantial improvement in performance, small companies experienced negative growth.
Large companies with sales of more than KRW 100 billion in the third quarter recorded an average growth rate of 9.4%. Mid-upper companies with sales of KRW 50-100 billion posted a 12.3% growth rate, while mid-lower companies with sales of KRW 25-50 billion achieved a 15.2% growth rate.
In contrast, small companies with sales of less than KRW 25 billion in the third quarter experienced a decline of 3.3%. Among the 15 small companies, two-thirds (10 companies) reported negative growth.
On the other hand, only 2 out of the 16 large companies recorded negative growth, while only 1 company among the 16 mid-upper companies and another 1 among the 16 mid-lower companies reported negative growth.
Among the 63 listed pharmaceutical companies analyzed, Bukwang Pharm recorded the highest sales growth at 111.2%, followed by Celltrion Pharm and Withus Pharmaceutical at 37.2% and 37.0%, respectively.
Additionally, Boryung Pharmaceutical and Jinyang Pharm saw their sales grow by over 30%, while Kyungdong Pharm, Dongkoo Bio & Pharma, Yuhan Corporation, Ahn-Gook Pharmaceutical, Kukje Pharma, ST Pharm, and JW Shinyak achieved growth rates exceeding 20%.
Other companies, including Dong-A ST, WhanIn Pharm, Daewon Pharm, JW Life Science, DongKook Pharmaceutical, Shinpoong Pharm, Samjin Pharm, HanAll Biopharma, and GC Biopharma, posted double-digit growth rates.
Sam Chun Dang Pharm, Myungmoon Pharm, Arlico Pharm, Daihan Pharm, Kyungbo Pharm, HK inno.N, Dongwha Pharm, Kwang Dong Pharmaceutical, Optus Pharmaceutical, CMG Pharmaceutical, and Ilsung Is also recorded growth rates exceeding 5%.
In addition, companies such as Yungjin Pharm, Daewoong Pharmaceutical, Chong Kun Dang Bio, Ildong Pharmaceutical, Samil Pharmaceutical, Hwail Pharmaceutical, Chong Kun Dang Pharmaceutical, Daehwa Pharmaceutical, Hana Pharm, Cho-A Pharm, Kyungnam Pharm, Reyon Pharm, Sinsin Pharm, Huons, Handok, Hanmi Pharmaceutical, and Korea United Pharm recorded growth rates within 5%.
In contrast, companies like Shinil Pharm and Korean Drug saw their sales plummet by 18.9% and 17.1%, respectively. Others, including Samsung Pharm, BCWorld Pharm, Sam-A Pharm, Il-Yang Pharm, JW Pharmaceutical, Yuyu Pharma, Korea Pharma, Dong Sung Bio Pharm, Hyundai Pharm, Jeil Pharm, Seoul Pharma, and Union Korea Pharm, also reported negative growth.
